文献速递血栓与止血

紫杉醇在缺乏血小板生成素受体(Mpl)的情况下改善血小板生成

Paclitaxel improves thrombopoiesis in the absence of thrombopoietin receptor (Mpl).
PubMed 文献 · J Thromb Haemost · 2024-09-20

本研究利用Tg(mpl:eGFP)斑马鱼模型进行药物筛选,发现紫杉醇可加速血小板谱系细胞增殖以扩增血小板,并在小鼠中升高血小板水平;该效应绕过血小板生成素受体(Mpl),可能涉及JAK2-ERK1/2 MAPK信号通路,且ERK1/2至少部分位于JAK2下游。

要点

  • 紫杉醇在斑马鱼中扩增血小板并加速血小板谱系细胞增殖。
  • 紫杉醇在小鼠中升高血小板水平,该效应绕过血小板生成素受体(Mpl)。
  • 紫杉醇促血小板生成可能涉及JAK2-ERK1/2 MAPK通路,ERK1/2至少部分位于JAK2下游。

核心结论

  • 紫杉醇可能通过绕过Mpl、推测经JAK2-ERK1/2 MAPK通路促进血小板生成。
  • 紫杉醇可能对保护血小板和改善相关疾病中的血小板增多具有潜在价值。

研究设计与样本

  • 研究采用Tg(mpl:eGFP)斑马鱼模型进行体内药物筛选,以识别能提升血小板生成的美国食品药品监督管理局(FDA)批准化合物。
  • 采用损伤实验评估血小板功能;采用溴脱氧尿苷(BrdU)检测、末端脱氧核苷酸转移酶dUTP缺口末端标记(TUNEL)和RNA测序分析探索细胞与分子机制。
  • 采用常规血液检测和流式细胞术分析小鼠表型。

主要发现

  • 紫杉醇通过加速斑马鱼血小板谱系细胞增殖来扩增血小板,并升高小鼠血小板水平。
  • 该效应通过绕过血小板生成素受体(Mpl)发生。
  • 紫杉醇促进血小板生成可能涉及JAK2-ERK1/2 MAPK信号级联,该通路是MPL和其他调控因子不可或缺的通路。
  • ERK1/2在紫杉醇诱导的血小板生成中至少部分位于JAK2下游。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platelets are critical for thrombosis and hemostasis. The THPO-MPL pathway is the primary pathway for generating thrombocytes. Dysregulation of thrombopoiesis results in platelet formation and/or function-related disorders, such as thrombocytopenia. Paclitaxel is an extensively utilized chemotherapeutic agent and its activity may be related to platelets, but the effect of paclitaxel on thrombocytopoiesis warrants comprehensive exploration. OBJECTIVES: We focused on identifying factors that regulate thrombocyte production and elucidating paclitaxel's regulatory mechanisms on thrombocytopoiesis, with a particular emphasis on discovering mechanisms that bypass THPO-MPL pathways. METHODS: We performed drug screenings using the Tg(mpl:eGFP) zebrafish model in vivo to identify Food and Drug Administration-approved compounds capable of boosting thrombocyte production. An injury experiment was used to evaluate thrombocyte function. Bromodeoxyuridine assays, terminal deoxynucleotidyl transferase dUTP nick-end labeling, and RNA sequencing analyses were performed to explore cytological and molecular mechanisms. Routine blood testing and flow cytometry were used to analyze mouse phenotypes. RESULTS: We found that paclitaxel expands thrombocytes by accelerating the proliferation of thrombocytic lineage cells in zebrafish and elevates platelet levels in mice. This effect occurs by bypassing the thrombopoietin receptor (Mpl). We found that paclitaxel promotes thrombopoiesis, potentially involving the JAK2-ERK1/2 MAPK signaling cascade, a pathway integral to MPL and other regulators. Our results further demonstrate that ERK1/2 is at least partially downstream of JAK2 in paclitaxel-induced thrombopoiesis. CONCLUSION: Paclitaxel could promote thrombopoiesis by bypassing Mpl but presumably via the JAK2-ERK1/2 MAPK pathways. It will aid in understanding the relationship between paclitaxel and platelets clinically, and paclitaxel may have potential value for safeguarding platelets and improving thrombocytosis in related diseases.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Meng P, Liu W, Lao J, et al. Paclitaxel improves thrombopoiesis in the absence of thrombopoietin receptor (Mpl). J Thromb Haemost. 2024. PMID: 39307245. doi:10.1016/j.jtha.2024.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。